The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here.
Largest Deals (365 days) Traded Action Notifier Price Amount Value 20-Nov Buy Kate Bleasdale 252.00p 50,000 £126,000.00 08-Sep Buy Kate Bleasdale 215.30p 10,000 £21,530.00 08-Sep Buy Alasdair Liddell 205.80p 3,862 £7,948.00 08-Sep Buy Alan Walker 227.00p 3,000 £6,810.00 08-Sep Buy Diane Jarvis 219.00p 2,270 £4,971.30 More Healthcare Locums director deals Director Shareholdings Notifier Holding Value* Kate Bleasdale 10,062,569 £22,665,937 Alan Walker 98,000 £220,745 Alasdair Liddell 75,152 £169,280 Diane Jarvis 54,773 £123,376 Mo Dedat 27,000 £60,818 Carole Hepburn 8,000 £18,020 Major Shareholders Notifier** Holding Value* Equinox Partners L.P. 17,598,158 £39,639,851 FIL Limited 5,484,410 £12,353,634 Barclays PLC 5,222,550 £11,763,794 JPMorgan Asset Management Holdings Inc. 5,146,629 £11,592,782 Octopus Investments Limited 3,129,352 £7,048,865
£327,426 224.82p 145,639 11:47 Buy O £168,728 224.97p 75,000 10:53 Buy O
Gartmore calls on FSA to alter Rambourg's status • Story by: Rob Langston • Magazine: FTAdviser • Published Wednesday , April 14, 2010 Gartmore has confirmed Guillaume Rambourg will not undertake any regulated activity while he is suspended after the manager had his status on the Financial Services Authority (FSA) register changed to "inactive". By being taken off the register, Mr Rambourg has ceased to be an approved person in the eyes of the regulator; however, this does not prevent him from being readmitted to the register at a later date. The fund manager has been suspended by Gartmore pending an internal investigation over claims that Mr Rambourg directed trades to brokers. A spokeswoman for Gartmore said: "When Guillaume was suspended, we were required to notify the FSA and submit a Form C which confirms that he will not be undertaking any activity as an approved person, until such a time that the suspension is lifted. "As a result, his registration will be inactive for the duration of his suspension. For the avoidance of doubt, his suspension is not a disciplinary step." A spokesperson for the Financial Services Authority said: "If an indivdual should be made inactive due to their death they would show as deceased on the register, other than that they become inactive when they cease to undertake a function for the firm that they had previously been approved under. "There are two ways this can happen: one, if the firm notifies us of this; or, two, if the FSA takes enforcement action to withdraw their approval
224>>>>>>>>
224.50>>>>>>>>>>>>>>>>>>>
Please read a letter from Richard Pursglove, Gartmore's Head of UK Retail, that should serve as a comprehensive update and explanation around our announcement last week and in particular addresses the issues reported in the press last week and over the weekend. Please do not hesitate to contact me at greg.mayho@gartmore.com should you have any questions, which we will endeavour to answer in full, ensuring you are kept fully appraised of the situation. Assuring you of our best attention at all times. http://v2.panaceaifa.com/img/20/documents/Gartmore%20Update%206%20April%202010.pdf
FORM 8.3 DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE (Rule 8.3 of the City Code on Takeovers and Mergers) 1. KEY INFORMATION Name of person dealing (Note 1) JGD Management Corp. Company dealt in Healthcare Locums Plc Class of relevant security to which the dealings being disclosed relate (Note 2) ORD 10 pence Date of dealing 9 April 2010 2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) Long Short Number (%) Number (%) (1) Relevant securities (2) Derivatives (other than options) 1,310,000 1.25% (3) Options and agreements to purchase/sell Total 1,310,000 1.25% (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) Class of relevant security: Long Short Number (%) Number (%) (1) Relevant securities (2) Derivatives (other than options) (3) Options and agreements to purchase/sell Total (c) Rights to subscribe (Note 3) Class of relevant security: Details 3. DEALINGS (Note 4) (a) Purchases and sales Purchase/sale Number of securities Price per unit (Note 5) (b) Derivatives transactions (other than options) Product name, e.g. CFD Long/short (Note 6) Number of securities (Note 7) Price per unit (Note 5) CFD Buy 640,000 2.4544 GBP CFD Buy 670,000 2.4284 GBP (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying Product name, e.g. call option Writing, selling, purchasing, varying etc. Number of securities to which the option relates (Note 7) Exercise price Type, e.g. American, European etc. Expiry date Option money paid/received per unit (Note 5) (ii) Exercising Product name, e.g. call option Number of securities Exercise price per unit (Note 5) (d) Other dealings (including new securities) (Note 4) Nature of transaction (Note 8) Details Price per unit (if applicable) (Note 5) 4. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. Is a Supplemental Form 8 attached? (Note 9) NO Date of disclosure 12 April 2010 Contact name George Kim Telephone number 001 212-300-1300 If a connecte
224>>>>>>>>>>>>.
he is a financial analyst and this his his educated view and nothing more?
230>>>>>
dropping fast
A friend seems to think the offer price is £2 per share which could be announced after the market closes today or before the market opens tomorrow?
A disclosure table, giving details of the companies in whose "relevant securities" "dealings" should be disclosed, and the number of such securities in issue, can be found on the Panel's website at www.thetakeoverpanel.org.uk. "Interests in securities" arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an "interest" by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities. Terms in quotation marks in the preceding paragraphs under the heading "Dealing disclosure requirements" are defined in the Code, which can also be found on the Panel's website. If you are in any doubt as to whether or not you are required to disclose a "dealing" under Rule 8 of the Code, you should consult the Panel. This announcement is not intended to and does not constitute, or form any part of, an offer or an invitation to purchase or sell any securities or the solicitation of an offer to purchase any securities in any jurisdiction pursuant to the Offer or otherwise
HEALTHCARE LOCUMS PLC (the "Company") Statement re. Possible Offer The Board of Healthcare Locums plc announces that it has received an approach which may or may not lead to an offer being made for the Company. A further announcement will be made as soon as possible. Pursuant to Rule 2.10 of the City Code on Takeovers and Mergers, Healthcare Locums plc would like to confirm that, as at the close of business on 8 April 2010, the issued share capital consisted of 105,167,601 ordinary shares of 10p each, none of which are held in treasury. Accordingly, the number of shares carrying voting rights is 105,167,601. The ISIN reference number for these securities is GB00B0MD8242. Contact information: Healthcare Locums plc Kate Bleasdale, Executive Vice Chairman Tel: 0207 451 1451 Fairfax I.S. PLC Ewan Leggat / Simon Bennett / Laura Littley Tel: 0207 598 5368 Pelham Bell Pottinger David Rydell / Emma Kent / Duncan Mayall Tel: 020 7337 1500 Fairfax I.S. PLC which is authorised and regulated in the United Kingdom by the Financial Services Authority for investment business, is acting exclusively for Healthcare Locums plc and for no-one else in relation to the proposed Offer and is not acting for any other person in relation to the proposed Offer. Fairfax will not be responsible to anyone other than Healthcare Locums plc for providing the protections afforded to its clients or for providing advice in relation to the proposed Offer, the contents of this announcement or any offer or arrangement referred in this announcement. Dealing disclosure requirements Under the provisions of Rule 8.3 of the Code, if any person is, or becomes, "interested" (directly or indirectly) in one per cent or more of any class of "relevant securities" of Healthcare Locums plc, all "dealings" in any "relevant securities" of Healthcare Locums plc (including by means of an option in respect of, or a derivative referenced to, any such "relevant securities") must be publicly disclosed by no later than 3.30 p.m. (London time) on the business day following the date of the relevant transaction. This requirement will continue until the date on which the Offer becomes, or is declared, unconditional as to acceptance, lapses or is otherwise withdrawn or on which the "Offer Period" otherwise ends. If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire an "interest" in "relevant securities" of Healthcare Locums plc they will be deemed to be a single person for the purpose of Rule 8.3 of the Code. Under the provisions of Rule 8.1 of the Code, all "dealings" in "relevant securities" of Healthcare Locums plc by Healthcare Locums plc or by any of their respective "associates" must be disclosed by no later than noon (London time) on the business day following the date of
MARKS AND SPENCER GROUP PLC QUARTER 4 2009/10 - TRADING STATEMENT 13 weeks to 27 March 2010 · Group sales +4.8% · UK sales* +6.2%: General Merchandise +10.6% (Clothing +10.1%; Home +13.3%); Food +2.6% · UK like for like sales* +5.1%: General Merchandise +9.1%; Food +1.8% · M&S Direct sales +48% · International sales -5.9% * The reported quarter this year includes the first day of the Christmas sale which was held on 27 December. This added c. 1.3% to UK and c. 2.9% to General Merchandise total and like for like sales. Marks & Spencer has delivered a strong performance over the quarter. Total UK sales were up 6.2% over the period, marking a further improvement in the trend seen over the last five quarters. Performance improved across all areas of General Merchandise, as customers continued to seek out affordable quality and style. Clothing market share was up 110bps to 11.9%1. Sales of formalwear and knitwear were particularly strong and we successfully launched our Spring collections with customers responding well to our interpretation of the season's key trends and fashions. Performance in Home was better across all the core ranges and technology. In Food, we have delivered a sixth consecutive quarter of improved performance, as better value, availability and product innovation have continued to drive improved like-for-like sales. We continue to be first to market with exciting new ranges such as 'Simply Fuller Longer' and are on track to launch over 1,500 new lines this year. M&S Direct had another strong quarter with sales up 48% as we extended 'Shop Your Way', our multi-channel ordering service, to over 300 stores. International sales were down 5.9%, as a result of particularly difficult trading conditions in the Republic of Ireland and Greece, and an adverse impact from currency translation. We expect profit before tax for 52 weeks of 2009/10 (to 27 March 2010) to be in the range of £620m to £630m. The 53rd week (to 3 April 2010) is expected to contribute an additional c.£60m of profit before tax. These figures reflect gross margin better than the guidance of -50 to -100 bps, and operating costs at the top end of the 0 to +1% range. As a result of out-performance against our plan for this year, we are paying a bonus of around £80m shared by all our employees. Sir Stuart Rose, Chairman said: "These are strong quarterly results by any measure. They demonstrate the appeal of the M&S brand to our 21 million weekly customers and its resilience in these difficult times. The continuing improvement in our performance is the result of the actions we have taken to invest in our stores, service, product and values. In clothing we have seen a substantial increase in market share and in food we have had six consecutive quarters of improving like-for-like performance.
Gartmore is pleased to announce the successful completion today of the joint venture with Hermes Fund Managers Limited to combine Private Equity fund of fund businesses into a new vehicle, Hermes GPE LLP. At inception, Hermes GPE LLP will have combined assets under management of £4.1 billion. vendor
Gartmore Announcement re Guillaume Rambourg Despite recent media coverage concerning an internal Gartmore investigation in connection with one of our senior fund managers, we would like to reassure our clients that it's very much a case of "business as usual" at Gartmore and we continue to manage our clients' investments in line with their objectives and policies. The internal investigation in progress has been instigated by Gartmore and relates to a potential breach of Gartmore's internal procedures. Our offices will be closed during the Easter Bank Holiday, however, if you do have questions you are welcome to contact your usual Gartmore representative or team during our regular office hours.
GOOD NEWS HAS JUST BEEN ANNOUNCED AFTER THE MARKETS CLOSED (There had been 'no material redemptions' since the decision to sideline Guillaume Rambourg) LONDON, March 31 (Reuters) - Clients of listed British fund manager Gartmore have been wary but have stuck by the firm after the suspension of a top fund manager suspected of breaching internal rules, said chief executive officer Jeff Meyer. There had been 'no material redemptions' since the decision to sideline Guillaume Rambourg -- the long-time colleague of Gartmore's star fund manager Roger Guy -- was announced on Tuesday, Meyer said in an interview with Reuters. 'Clients greatly appreciated hearing about it from us but the reaction has been guarded,' he said. Meyer also confirmed that Rambourg was suspected of directing the company's dealers to use certain brokers when conducting trades, but he said no single broker appeared to have received the lion's share of any favour. News of the suspension raised the prospect of redemptions from concerned clients, and Gartmore shares slumped by more than 30 percent to close at 116 pence on Tuesday. By 1507 GMT on Wednesday, the shares had rallied back by around 10 percent. The stock had listed at 220 pence in December.
I agree this share is waiting for something? May be they will be bought out this time? or they will look again for further acquisitions either way I can see this share rise to 45+ 30% + real quick (may be in the first few months as the statement reports Sales in the first two months of 2010 have been slightly ahead of our expectations?
Don't know what happened yesterday? 20% + Rise today Healthcare Locums PLC ("HCL", "the Company" or "the Group") Final results for the year ended 31 December 2009 Financial Highlights · Revenue increased by 5% to £172.1m (2008 restated: £164.5m) · Gross margin increased by 23% to £52.9m (2008 restated: £43.1m) · Adjusted operating profit* increased by 31% to £25.2m (2008 restated: £19.3m), despite adoption of longer term permanent placement income accounting policy · Operating profit increased by 18% to £19.7m (2008 restated: £16.7m) · Net margin as a percentage increased by 13% to 11.5% (2008 restated: 10.2%) · Adjusted net margin** as a percentage increased by 25% to 14.6% (2008 restated: 11.7%) · Adjusted profit before tax*** increased by 41% to £23.2m (2008 restated: £16.5m) · Profit before tax increased by 27% to £17.7m (2008 restated: £13.9m) · Adjusted basic earnings per share**** increased by 37% to 16.0 pence (2008 restated: 11.7 pence) · Basic earnings per share increased by 24% to 12.3 pence (2008 restated: 9.9 pence) · Net debt has fallen to £17.3m (2008: £26.9m) · Second interim dividend of 1.5p announced to be paid on 1 April 2010 · Final proposed dividend of 1.9p per share to be declared by the Board bringing total dividend for 2009 to 5.0p (2008: 2.0p per share) Operational Highlights · Strong organic like-for-like gross profit growth rate of 23% (2008 restated: 44%) · International permanent placement division a key growth driver - delivering strong pipeline in the second half of 2009 · The passing of President Obama's healthcare reforms is likely to increase demand for the 12,500 international candidates now on our database · The US needs 1.2m new nurses by 2014, this is now expected to increase to circa 1.6m · Demand for healthcare staff continues to grow from the NHS with a 20% increase in the market between 2008-2009 (Laing and Buisson 2010) · Growing proportion of private sector business, particularly internationally · Strategic shift towards higher margin permanent placements - International & UK permanent placements together now contribute 10.2% of Group gross margin (2008 restated: 6.0%) · Global networks becoming increasingly important in meeting our clients' needs in the UK · New offices opened in Australia, Canada and the Middle East · US operation continues successful expansion · Continued streamlining of back office and support functions resulted in significant cost savings and improved adjusted net margin percentage** to 15% (2008 restated: 12%)